Sareum Share Discussion Threads

[aberystwyth] 01/7/2024 12:41

Huge license deal being worked on as we speak No serious side effects - no efficacy issues Already financed from placing - tax rebate expected - 27.5% of £1 million + 27.5% of 500k shares in company x (737) by EOYNon- dilutive funding being worked through as part of 1801 deal All looks good to me ... don't panic iamhappy1 ... those imaginary shares you hold should only go up over time ... unless you are short ? Maybe we need to ask your misses about that though

[criticalthinker1] 01/7/2024 10:21

The timing of the RNS is very 'timely' re the situation over at GSK.....

[barkbooo] 01/7/2024 09:40

They won’t up the price, and they won’t sell you the stock - why is it called a market?

[ct8637] 01/7/2024 08:17

Definitely looks like it doesn't it, the 13 whole shares bought today...

[barkbooo] 01/7/2024 08:14

lol - the casino trying to bluff this…..it ain’t going to work my friends….a few big punters can’t get on and the casino won’t be able to hold this - happy times!

[ackkers] 01/7/2024 08:11

WolfandPeas... Aww diddums

[blackhorse23] 01/7/2024 08:10

Money moved to rank group [RNK]

[barkbooo] 01/7/2024 07:41

Silver - try and get on for even small money first thing..auction, auction, auction is my guess.

[silvergreyhead1] 01/7/2024 07:38

Nice RNS, maybe a bit understated but that's typical of Sareum.It will do for now.

[yzf750] 01/7/2024 07:32

Sareum Holdings plc("Sareum" or the "Company")Positive Data from SDC-1801 Phase 1 Clinical TrialCambridge, UK, 1 July 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce positive topline data from its Phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases.Following the dosing of the final cohort in the Multiple Ascending Dose stage of the trial, and review of the initial data by the Safety Review Committee, the Company reports that:· Blood plasma levels of SDC-1801 significantly in excess of the predicted therapeutic exposure were achieved, with a half-life of between 17 and 20 hours observed, which suggests that once-daily dosing will be possible*· No deaths or serious adverse events due to SDC-1801 were reported· Although data remains blinded, there appear to be no significant changes in blood cell counts or increases in serum creatinine levels, which may be dose limiting side-effects of brepocitinib, currently the most advanced TYK2/JAK1 dual inhibitor *Half-life is an estimation of the time it takes for an initial concentration of SDC-1801 to be reduced by half in the body.The Company expects that further data, unblinded from drug/placebo recipients, including details of any mild or moderate adverse events and biomarkers of TYK2 and/or JAK1 inhibition, will be available in Q3 2024.Dr Tim Mitchell, Chief Executive Officer of Sareum, commented: "We are delighted that the dosing of subjects in the SDC-1801 clinical trial has been completed successfully and without any serious adverse events. We look forward to building a strong data package to advance SDC-1801 to the next stage of its development." Dr John Reader, Chief Scientific Officer of Sareum, added: "The success of this stage of the clinical trial demonstrates that high blood levels of a dual TYK2/JAK1 kinase inhibitor can be achieved without serious side effects. Together with the long half-life observed, we believe this potentially gives SDC-1801 significant advantages over its competitors. We're grateful to the volunteers who participated in this trial, and to the clinical staff who enabled its timely completion."- END -

[barkbooo] 01/7/2024 07:32

The three planks will be slashing their wrists this morning - I did warn them..to think the price we were offered in late April. lol

[barkbooo] 01/7/2024 07:18

I think we might enjoy a good day - spookily quiet.

[wolfskinrug] 28/6/2024 22:43

Criticalthinker - if the lupus trials showed promise why did SRI & Uncle Sam not fund it further as they could have easily found a replacement for Dr. Trigunaite?

[criticalthinker1] 28/6/2024 19:37

Bon soir.

I appreciate SOG had a like of Michelle Garrett, but it's worth pointing out that she worked with Mark Kowalski.

At Sierra Oncology.

His latest appointment write up....

Eupraxia's lead product candidate, EP-104IAR, is currently in Phase 2 development for the treatment of pain due to osteoarthritis of the knee. The EP-104 platform has expanded into gastrointestinal disease with the launch of a Phase 1b/2a program to treat eosinophilic esophagitis. Eupraxia is also developing a pipeline of later- and earlier-stage long-acting formulations. Potential pipeline indications include candidates for both other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs.

All best Steadydanny

[criticalthinker1] 26/6/2024 22:53

I assume you have seen the recent protocol from Canada and trying to get vaccine mandates in again to travel....and live

[criticalthinker1] 26/6/2024 22:10

I applaude your enthusiasm wos...and upticks...so the advfn posters are listening.
What specifically re the science here are you specifically engaged with?
Is it the DDR arena or the specific interleukins that Sareum are focusing on?
Or global interest in treatments that are required but not msm yet?
Best regards Steadydanny

[wolfoffoolstreets] 25/6/2024 08:47

I see my old pal Wolfie is no more. Must be killing him not to be spending every moment of the day on this board. Perhaps he’s actually managed to get out and get some fresh air.

Can’t wait for a profile to appear in a few weeks, blurting out all the same BS as Wolfie and then absolutely denying that he’s the same person……just like he has over and over again.

[criticalthinker1] 24/6/2024 21:49

Finally

SRA737 is a clinical-stage oral, selective checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms

Sareum said an immediate upfront payment of $500,000 is due to CRT Pioneer Fund.

Sareum said an additional fee made up of up to $1.0 million cash and 500,000 shares in the licensee company may be payable upon the sooner 12 months following the signing of the licencing agreement, or if the licensee company achieves certain commercial and material financing objectives.

It said a further announcement regarding any future income, including any shares which may be issued, will be made ‘at the appropriate time’...............................

[criticalthinker1] 24/6/2024 21:24

This extract from the link...which you have to click on read thread


Results showed that SRA737 could relieve MDA-MB-231 cells’ cell cycle arrest in the G2/M phase which was reduced by DOX. It is widely established that DNA damage generated by photoirradiation [43], radiotherapy [36], genotoxic agents [39], or even plant extract derivatives [44] may temporarily induce the arrest of the cell cycle, allowing time for repair. The G2/M checkpoint is critical for avoiding premature mitosis in cells with damaged DNA, particularly those lacking functioning p53 [45]. Interestingly, the MDA-MB-231 human breast cancer cell line has high levels of a mutant p53, so the arrest in the G2/M phase caused by the genotoxic agent DOX is readily comprehensible. After treatment with SRA737, the G2/M phase arrest was relieved, which may be attributed to the inhibited CHK1. As a master modulator of the DNA damage response, the regulation of cell cycle progression, repair of DNA damage, and DNA replication of CHK1 were all affected, thereby facilitating excessive damage of DNA and decreasing the fitness of overall survival of the tumor cells.

And one more extract from this to follow

[criticalthinker1] 24/6/2024 20:04

Very interesting reading today.

Note that eFFECTIVE Therapeutics have effectively closed shop.

Now SRA737 has shown great potential in that arena...



The above from July 2022.

There are other reports if you look up medchemexpress with SRA737
Medchemexpress market the drug...I believe I'm correct there.

So a promising drug in multiple applications is effectively just deemed not part of the negotiations with Sierra Oncology...but its all about momo...just dosnt add up

GSK missed out to Pfizer on a contract with the UK government....albeit its links to respiratory considerations (1801)...but it was part of the tendering process....was it cost over results...Will delve deeper.

Something is brewing here.

Is there news in the corridors of the pharma world that some novel drugs are about to do an Italian Job?
As in literally blow the doors off multiple companies ipr platforms?
So are they closing down their research knowing the fat lady is having a gargle with warm honey and getting the vocal chords ready....twitter seemed positive today...some careful use of words knowing how they can be interpreted/overly interpreted.

All best Steadydanny

[norma_stitts] 24/6/2024 11:22

A highly illiquid stock (LME) with a pittance market cap that has only had 4 days in the last 3 months where ANY shares have traded does not make a good investment. Heck, today is the first time in 7 weeks that anyone has done any form of trades!?! 😂😂😂

A measly £500 worth of trades moved it almost 15% and you’re coming on here talking about technical analysis when you’ve a handful of data points in the last 3 months? Pull the other one sunshine.

Now, as you’re clearly not here to discuss SAR and you’re clearly here to spam some utter tat, kindly go back to your LME board, there’s a good chap. 👍